Yu-Tze Ng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Yu-Tze Ng has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Afsaneh Talai
University of Oklahoma College of Medicine, Oklahoma City, Oklahoma
1 shared publication- David M. Thompson
University of Oklahoma Health Sciences Center
1 shared publication Deborah Lee
1 shared publication- Donald L. Harrison
College of Pharmacy, University of Oklahoma, Oklahoma City, USA
1 shared publication Gabriela Purcarin
Department of Neurology, University of Oklahoma, Oklahoma City, OK, USA
1 shared publicationJ. Stolle
From the St. Joseph's Hospital Medical Center and Barrow Neurological Institute (Y.T.N.), Phoenix, AZ; Children's National Medical Center (J.A.C.), Washington, DC; and Lundbeck Inc. (R.D., J.S., M.A.W.), Deerfield, IL
1 shared publication
Latest Publications
- Open Access
- 1 May 2014
- Published by Elsevier in Epilepsy & Behavior
- Vol. 34, 109-115
Have antiepileptic drug prescription claims changed following the FDA suicidality warning? An evaluation in a state Medicaid program
- 1 May 2014
- Published by Elsevier in Epilepsy & Behavior
- Vol. 34, 109-115
Open AccessHave antiepileptic drug prescription claims changed following the FDA suicidality warning? An evaluation in a state Medicaid program
- 4 February 2014
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 7 (3) , 169-176
Experience in the use of clobazam in the treatment of Lennox–Gastaut syndrome
Clobazam is a 1,5-benzodiazepine used successfully worldwide since the 1970s as an anxiolytic and antiepileptic drug. Since its recent Food and Drug Administration (FDA) approval in the United States in 2011 as adjunctive treatment for Lennox–Gastaut syndrome, it has continued to show sustained efficacy and a better safety and tolerability profile compared with other benzodiazepines. The two randomized, controlled studies that led to the US FDA approval, as well as the follow-up multicenter, open-label study of clobazam, showed ≥50% seizure reduction for more than 50% of Lennox–Gastaut syndrome patients, while none of the other FDA-approved treatments for LGS have demonstrated efficacy rates better than 50%. Clobazam appears to have a safe profile and sustained effectiveness over the first 3 years of use in LGS and other epilepsy syndromes with intractable seizures, which makes it a viable long-term treatment option.
- 4 February 2014
- Published by SAGE Publications in Therapeutic Advances in Neurological Disorders
- Vol. 7 (3) , 169-176
Experience in the use of clobazam in the treatment of Lennox–Gastaut syndrome
Clobazam is a 1,5-benzodiazepine used successfully worldwide since the 1970s as an anxiolytic and antiepileptic drug. Since its recent Food and Drug Administration (FDA) approval in the United States in 2011 as adjunctive treatment for Lennox–Gastaut syndrome, it has continued to show sustained efficacy and a better safety and tolerability profile compared with other benzodiazepines. The two randomized, controlled studies that led to the US FDA approval, as well as the follow-up multicenter, open-label study of clobazam, showed ≥50% seizure reduction for more than 50% of Lennox–Gastaut syndrome patients, while none of the other FDA-approved treatments for LGS have demonstrated efficacy rates better than 50%. Clobazam appears to have a safe profile and sustained effectiveness over the first 3 years of use in LGS and other epilepsy syndromes with intractable seizures, which makes it a viable long-term treatment option.
- 1 February 2014
- Published by Elsevier in Pediatric Neurology
- Vol. 50 (2) , 195-196
Redefining the “Hyperphotoconvulsive” Response of Late-Infantile Neuronal Ceroid Lipofuscinosis
- 1 February 2014
- Published by Elsevier in Pediatric Neurology
- Vol. 50 (2) , 195-196
Redefining the “Hyperphotoconvulsive” Response of Late-Infantile Neuronal Ceroid Lipofuscinosis
- 1 June 2013
- Published by Elsevier in Epilepsy & Behavior
- Vol. 27 (3) , 472-476
“Simple febrile seizures plus (SFS+)”: More than one febrile seizure within 24hours is usually okay
- 1 June 2013
- Published by Elsevier in Epilepsy & Behavior
- Vol. 27 (3) , 472-476
“Simple febrile seizures plus (SFS+)”: More than one febrile seizure within 24hours is usually okay
- Open Access
- 1 December 2012
- Published by Elsevier in Epilepsy & Behavior
- Vol. 25 (4) , 687-694
Long-term safety and efficacy of clobazam for Lennox–Gastaut syndrome: Interim results of an open-label extension study
- 1 December 2012
- Published by Elsevier in Epilepsy & Behavior
- Vol. 25 (4) , 687-694
Open AccessLong-term safety and efficacy of clobazam for Lennox–Gastaut syndrome: Interim results of an open-label extension study
- 13 September 2012
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 49 (6) , 432-437
Status epilepticus in childhood
Status epilepticus (SE) remains a life-threatening condition that afflicts both adults and children, and may occur at onset of epilepsy, especially in children. Febrile SE is the most common cause in children, while other symptomatic causes are less frequent compared to adults. The aetiological workup that must be undertaken in all cases includes neuroimaging and electroencephalography. The various electroencephalographic patterns seen in patients with SE along with the out-of-hospital treatment for SE in children and treatment strategies in cases that are refractory to first-line medical treatments are discussed. Medically induced coma may be necessary in refractory cases, although the optimal agents to use and degree of electroencephalographic suppression in children remain unclear. Neurosurgery is not a well-known treatment option that could be considered for refractory cases. Although the prognosis has probably improved over the years, it remains a potential life-threatening emergency.
- 13 September 2012
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 49 (6) , 432-437
Status epilepticus in childhood
Status epilepticus (SE) remains a life-threatening condition that afflicts both adults and children, and may occur at onset of epilepsy, especially in children. Febrile SE is the most common cause in children, while other symptomatic causes are less frequent compared to adults. The aetiological workup that must be undertaken in all cases includes neuroimaging and electroencephalography. The various electroencephalographic patterns seen in patients with SE along with the out-of-hospital treatment for SE in children and treatment strategies in cases that are refractory to first-line medical treatments are discussed. Medically induced coma may be necessary in refractory cases, although the optimal agents to use and degree of electroencephalographic suppression in children remain unclear. Neurosurgery is not a well-known treatment option that could be considered for refractory cases. Although the prognosis has probably improved over the years, it remains a potential life-threatening emergency.
- 30 March 2012
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 27 (4) , 492-495
Lacosamide in Refractory Mixed Pediatric Epilepsy: A Prospective Add-on Study
Lacosamide is a new antiepileptic drug that is currently approved by the US Food and Drug Administration (FDA) for adults 17 years or older for partial-onset seizures. The authors reviewed 21 pediatric patients (<17 years) with various seizure types who were started on oral lacosamide as part of a prospective add-on study as adjunctive therapy for refractory epilepsy. Five patients were excluded due to less than 3 months of meaningful follow-up. Maintenance dosages used ranged from 2.4 to 19.4 mg/kg/d. Eight of 16 (50%) patients had greater than 50% reduction in seizure frequency with adjunctive lacosamide therapy. Eight (50%) patients had generalized epilepsy including 4 with Lennox-Gastaut syndrome. Lacosamide was effective therapy for most seizure types but was particularly effective for partial-onset seizures. Lacosamide was effective in treating 5 of 8 (62.5%) localization-related epilepsies but only 2 of 8 (25%) generalized epilepsies, both Lennox-Gastaut syndrome patients with greater than 90% seizure reduction. None of these very refractory patients remained seizure free.
- 30 March 2012
- Published by SAGE Publications in Journal of Child Neurology
- Vol. 27 (4) , 492-495
Lacosamide in Refractory Mixed Pediatric Epilepsy: A Prospective Add-on Study
Lacosamide is a new antiepileptic drug that is currently approved by the US Food and Drug Administration (FDA) for adults 17 years or older for partial-onset seizures. The authors reviewed 21 pediatric patients (<17 years) with various seizure types who were started on oral lacosamide as part of a prospective add-on study as adjunctive therapy for refractory epilepsy. Five patients were excluded due to less than 3 months of meaningful follow-up. Maintenance dosages used ranged from 2.4 to 19.4 mg/kg/d. Eight of 16 (50%) patients had greater than 50% reduction in seizure frequency with adjunctive lacosamide therapy. Eight (50%) patients had generalized epilepsy including 4 with Lennox-Gastaut syndrome. Lacosamide was effective therapy for most seizure types but was particularly effective for partial-onset seizures. Lacosamide was effective in treating 5 of 8 (62.5%) localization-related epilepsies but only 2 of 8 (25%) generalized epilepsies, both Lennox-Gastaut syndrome patients with greater than 90% seizure reduction. None of these very refractory patients remained seizure free.
- 11 October 2011
- Published by Wolters Kluwer Health in Neurology
- Vol. 77 (15) , 1473-1481
Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome
To evaluate efficacy and safety of clobazam, a 1,5-benzodiazepine, as adjunctive therapy for Lennox-Gastaut syndrome (LGS). Patients aged 2-60 years were randomized to placebo or clobazam 0.25, 0.5, or 1.0 mg/kg/day. Study consisted of 4-week baseline, 3-week titration, and 12-week maintenance phases, followed by a 2- or 3-week taper or continuation in an open-label extension. Primary endpoint was percentage decrease in mean weekly drop seizure rates during maintenance vs baseline phases for modified intention-to-treat (mITT) population. Secondary outcomes included other seizure types, responder rates, and physicians' and caregivers' global assessments. A total of 305 patients were screened, 238 were randomized, and 217 composed the mITT population. Of patients enrolled after a protocol amendment, 125/157 (79.6%) completed. Average weekly drop seizure rates decreased 12.1% for placebo vs 41.2% (p = 0.0120), 49.4% (p = 0.0015), and 68.3% (p < 0.0001) for the clobazam 0.25-, 0.5-, and 1.0-mg/kg/day groups. Responder rates (≥50%) were 31.6% (placebo) vs 43.4% (p = 0.3383), 58.6% (p = 0.0159), and 77.6% (p < 0.0001) for clobazam 0.25-, 0.5-, and 1.0-mg/kg/day groups. Physicians' and caregivers' assessments indicated clobazam significantly improved symptoms. Somnolence, pyrexia, upper respiratory infections, and lethargy were the most frequent adverse events reported for clobazam. Clobazam significantly decreased weekly drop seizure rates in LGS. No new safety signals were identified. This study provides Class II evidence that clobazam as adjunctive therapy is efficacious, in a dosage-dependent manner, in reducing mean weekly drop seizure rates of patients with LGS over 12 weeks.
- 11 October 2011
- Published by Wolters Kluwer Health in Neurology
- Vol. 77 (15) , 1473-1481
Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome
To evaluate efficacy and safety of clobazam, a 1,5-benzodiazepine, as adjunctive therapy for Lennox-Gastaut syndrome (LGS). Patients aged 2-60 years were randomized to placebo or clobazam 0.25, 0.5, or 1.0 mg/kg/day. Study consisted of 4-week baseline, 3-week titration, and 12-week maintenance phases, followed by a 2- or 3-week taper or continuation in an open-label extension. Primary endpoint was percentage decrease in mean weekly drop seizure rates during maintenance vs baseline phases for modified intention-to-treat (mITT) population. Secondary outcomes included other seizure types, responder rates, and physicians' and caregivers' global assessments. A total of 305 patients were screened, 238 were randomized, and 217 composed the mITT population. Of patients enrolled after a protocol amendment, 125/157 (79.6%) completed. Average weekly drop seizure rates decreased 12.1% for placebo vs 41.2% (p = 0.0120), 49.4% (p = 0.0015), and 68.3% (p < 0.0001) for the clobazam 0.25-, 0.5-, and 1.0-mg/kg/day groups. Responder rates (≥50%) were 31.6% (placebo) vs 43.4% (p = 0.3383), 58.6% (p = 0.0159), and 77.6% (p < 0.0001) for clobazam 0.25-, 0.5-, and 1.0-mg/kg/day groups. Physicians' and caregivers' assessments indicated clobazam significantly improved symptoms. Somnolence, pyrexia, upper respiratory infections, and lethargy were the most frequent adverse events reported for clobazam. Clobazam significantly decreased weekly drop seizure rates in LGS. No new safety signals were identified. This study provides Class II evidence that clobazam as adjunctive therapy is efficacious, in a dosage-dependent manner, in reducing mean weekly drop seizure rates of patients with LGS over 12 weeks.